Shares of Healthcare sector stock EnteroMedics Inc (NASDAQ:ETRM) surged +84.01 percent and closed at $3.85, during the current trading session. The share price of ETRM is currently trading within the range of $2.45 – $4.98. The company has a market capitalization of $11.50 Million, whereas its total outstanding shares are 2.39 million. Company’s beta value stands at 2.10 points. EnteroMedics’s current trading volume is 8.44 million, while its average volume is 318,444.00 shares.
EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, recently declared that the Company’s vBloc® Neurometabolic Therapy has now been implanted at two additional vBloc Institutes – MedStar Health in Maryland and Roper St. Francis in South Carolina. In order to qualify as a vBloc Institute, a medical center or hospital system must have integrated the Company’s vBloc Therapy and its vBloc® Achieve support program into its practice. MedStar Health and Roper St. Francis are the twelfth and thirteenth vBloc Institute programs to have integrated vBloc Therapy and the vBloc® Achieve care delivery program into their practice to fight obesity. vBloc Institutes have formerly been established at the following medical centers/hospital systems: VA North Texas Health Care System: Dallas VA Medical Center, NIX Medical (San Antonio), Hartford Hospital, Hackensack University Medical Center, South Florida Surgery and Bariatric Institute, University of Texas Medical Branch (UTMB), Smart Dimensions Weight Loss, Christiana Institute of Advanced Surgery (CHRIAS), Beltline Surgery Center, Winthrop University Hospital and Sky Ridge Medical Center.
vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally-invasive procedure that does not alter or remove any patient anatomy. This device can be adjusted to optimize patients’ therapy needs. Patients feel the sensation of fullness, empowering them to eat less, control their appetite, make healthier choices and lose weight without the major lifestyle implications of traditional weight loss surgeries.
vBloc Achieve is a comprehensive, personalized weight loss support program to assist vBloc patients reach and maintain health aims. While vBloc Therapy addresses hunger signals and cravings, vBloc Achieve provides emotional support and assists patients make positive lifestyle changes, counting health, balanced eating and regular exercise that are essential to long-term weight-loss success.
vBloc Therapy is approved for use in assisting with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.